bevacizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4956	216974-75-3

Description:

Molecule	Description
Synonyms: bevacizumab-awwb mvasi bevacizumab avastin rhuMAb-VEGF bevacituzumab bevacizumab (genetical recombination) bevacizumab biosimilar 3 bevacizumab biosimilar 4	An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

bevacizumab-awwb
mvasi
bevacizumab
avastin
rhuMAb-VEGF
bevacituzumab
bevacizumab (genetical recombination)
bevacizumab biosimilar 3
bevacizumab biosimilar 4

An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
April 18, 2007	PMDA	Chugai Pharmaceutical
Dec. 1, 2005	EMA	Roche Registration Limited
Feb. 26, 2004	FDA	GENENTECH

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	3230.42	13.59	2341	122876	120417	63243388
Death	3050.03	13.59	3708	121509	370673	62993132
Proteinuria	1597.63	13.59	772	124445	18373	63345432
Gastrointestinal perforation	1151.55	13.59	380	124837	3111	63360694
Hypertension	1110.95	13.59	1979	123238	277324	63086481
Off label use	900.39	13.59	3140	122077	671322	62692483
Endophthalmitis	853.74	13.59	306	124911	3286	63360519
Malignant neoplasm progression	788.80	13.59	889	124328	81232	63282573
Neutrophil count decreased	776.95	13.59	741	124476	55665	63308140
Palmar-plantar erythrodysaesthesia syndrome	743.46	13.59	499	124718	22516	63341289

Showing 1 to 10 of 738 entries

Previous1 2 3 4 5…74Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	1997.45	13.74	1937	94641	106140	34754213
Death	1366.06	13.74	3223	93355	394826	34465527
Proteinuria	1136.02	13.74	683	95895	17959	34842394
Gastrointestinal perforation	755.63	13.74	313	96265	3550	34856803
Off label use	718.96	13.74	2658	93920	416866	34443487
Endophthalmitis	628.40	13.74	267	96311	3241	34857112
Palmar-plantar erythrodysaesthesia syndrome	455.57	13.74	375	96203	16420	34843933
Myelosuppression	368.55	13.74	353	96225	18912	34841441
Drug interaction	338.88	13.74	102	96476	225844	34634509
Hypertension	310.51	13.74	954	95624	135489	34724864

Showing 1 to 10 of 546 entries

Previous1 2 3 4 5…55Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	3442.23	12.68	2963	166571	181399	79393455
Proteinuria	2344.23	12.68	1216	168318	31286	79543568
Gastrointestinal perforation	1188.90	12.68	459	169075	5678	79569176
Hypertension	1179.71	12.68	2337	167197	328655	79246199
Endophthalmitis	1168.25	12.68	459	169075	5969	79568885
Myelosuppression	1036.61	12.68	783	168751	39513	79535341
Palmar-plantar erythrodysaesthesia syndrome	965.24	12.68	694	168840	32440	79542414
Neuropathy peripheral	937.40	12.68	1320	168214	139985	79434869
Death	893.52	12.68	2936	166598	563578	79011276
Neutrophil count decreased	841.56	12.68	1018	168516	92941	79481913

Showing 1 to 10 of 925 entries

Previous1 2 3 4 5…93Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FG01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
ATC	S01LA08	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
FDA EPC	N0000193543	Vascular Endothelial Growth Factor Inhibitor
FDA MoA	N0000178291	Vascular Endothelial Growth Factor-directed Antibody Interactions
FDA MoA	N0000193542	Vascular Endothelial Growth Factor Inhibitors
MeSH PA	D020533	Angiogenesis Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Secondary malignant neoplasm of colon	indication	94260004
Liver cell carcinoma	indication	109841003	DOID:684
Malignant neoplasm of breast	indication	254837009	DOID:1612
Malignant epithelial tumor of ovary	indication	254849005
Carcinoma of cervix	indication	285432005	DOID:2893
Malignant tumor of fallopian tube	indication	363444001	DOID:1964
Malignant tumor of peritoneum	indication	363492001
Glioblastoma multiforme	indication	393563007
Nonsquamous nonsmall cell neoplasm of lung	indication	440173001
Metastatic renal cell carcinoma	indication	702392008

Showing 1 to 10 of 15 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vascular endothelial growth factor A	Secreted	P15692	VEGFA_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
008586	NDDF
017340	NDDF
18086	MMSL
2046138	RXNORM
267594	MMSL
2S9ZZM9Q9V	UNII
33386	MMSL
4021437	VUID
4021437	VANDF
4038596	VANDF

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALYMSYS	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1754	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	24 sections
ALYMSYS	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1755	INJECTION, SOLUTION	400 mg	INTRAVENOUS	BLA	24 sections
Avastin	HUMAN PRESCRIPTION DRUG LABEL	1	50242-060	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	28 sections
Avastin	HUMAN PRESCRIPTION DRUG LABEL	1	50242-060	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	28 sections
Avastin	HUMAN PRESCRIPTION DRUG LABEL	1	50242-061	INJECTION, SOLUTION	400 mg	INTRAVENOUS	BLA	28 sections
Avastin	HUMAN PRESCRIPTION DRUG LABEL	1	50242-061	INJECTION, SOLUTION	400 mg	INTRAVENOUS	BLA	28 sections
MVASI	HUMAN PRESCRIPTION DRUG LABEL	1	55513-206	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	30 sections
MVASI	HUMAN PRESCRIPTION DRUG LABEL	1	55513-206	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	30 sections
MVASI	HUMAN PRESCRIPTION DRUG LABEL	1	55513-206	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	30 sections
MVASI	HUMAN PRESCRIPTION DRUG LABEL	1	55513-207	INJECTION, SOLUTION	400 mg	INTRAVENOUS	BLA	30 sections

Showing 1 to 10 of 18 entries

Previous1 2Next